Trilaciclib
CAS NO.: 1374743-00-6
MF: C24H30N8O
MF: C24H30N8O
API235
Quantity
![]()

Trilaciclib is a small molecule, competitive inhibitor of cyclin dependent kinases 4 and 6 (CDK4/6),
with potential antineoplastic and chemoprotective activities.
![]()
Trilaciclib is indicated to reduce the frequency of chemotherapy-induced bone marrow suppression
in adults receiving certain types of chemotherapy for extensive-stage (when the cancer has spread beyond the lungs) small cell lung cancer.
It has a short duration of action of approximately 16 hours, and a narrow therapeutic index.
Patients should be counselled regarding the risk of injection site reactions, hypersensitivity, and interstitial lung disease.



